20
The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies.
 patients with advanced NSCLC: Subject; enhances the activity of cisplatin: Effect; tirapazamine: Treatment; tirapazamine: Treatment.Drug; advanced NSCLC: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with advanced NSCLC: Subject; enhances the activity of cisplatin: Effect; tirapazamine: Treatment; tirapazamine: Treatment.Drug; advanced NSCLC: Treatment.Disorder